# Boswellic Acids (Boswellia serrata)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/boswellic-acids-boswellia-serrata
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Boswellia serrata resin acids, Frankincense triterpenoids, Shallaki extract, AKBA, KBA, Indian olibanum acids, BSE boswellic acids

## Overview

Boswellic acids, particularly 3-O-acetyl-11-keto-β-boswellic acid (AKBA), exert [anti-inflammatory](/ingredients/condition/inflammation) effects primarily by inhibiting 5-lipoxygenase (5-LOX) with an IC50 of approximately 0.6–15 µM, while also modulating NF-κB, MAPK, COX-2, and the NLRP3 inflammasome. Small clinical pharmacokinetic studies and preclinical trials support their utility in inflammatory conditions such as osteoarthritis, though large-scale randomized controlled trials remain limited and evidence of clinical benefit is still emerging.

## Health Benefits

- **[Anti-Inflammatory](/ingredients/condition/inflammation) Activity**: AKBA and KBA inhibit 5-lipoxygenase at nanomolar-to-micromolar concentrations, reducing leukotriene biosynthesis and suppressing NF-κB signaling, which collectively attenuate systemic and local inflammatory cascades relevant to arthritis and inflammatory bowel conditions.
- **Joint Health and Osteoarthritis Support**: Standardized Boswellia serrata extracts (BSE) have been examined in small clinical studies for reducing knee pain and improving mobility in osteoarthritis patients, with mechanisms linked to 5-LOX inhibition reducing pro-inflammatory eicosanoids in synovial tissue.
- **Antioxidant Defense via Nrf2 Activation**: In non-immune cell types, boswellic acids activate the Nrf2 transcription factor pathway, upregulating endogenous antioxidant enzymes such as heme oxygenase-1 and glutathione peroxidase, counteracting [oxidative stress](/ingredients/condition/antioxidant)-driven tissue damage.
- **[Immune Modulation](/ingredients/condition/immune-support) and Phagocytosis Priming**: Boswellic acids modulate innate immune responses by priming phagocytic activity in macrophages and neutrophils, promoting vesicle trafficking and [autophagy](/ingredients/condition/longevity), which may support resolution of chronic inflammatory states without broad immunosuppression.
- **Antimicrobial Synergy**: Boswellic acids demonstrate antibacterial properties against Gram-positive organisms and exhibit synergistic activity when combined with conventional antibiotics, suggesting potential adjunctive utility in managing bacterial infections, though clinical data in this area is sparse.
- **Neuroprotective Potential**: Animal studies have detected KBA and AKBA in brain tissue at concentrations of approximately 95–99 ng/g following oral dosing, indicating blood-brain barrier penetration and raising the possibility of central anti-inflammatory and [neuroprotective effect](/ingredients/condition/cognitive)s warranting further investigation.
- **[Hepatoprotective](/ingredients/condition/detox) Effects**: Traditional use and preliminary experimental data attribute hepatoprotective properties to Boswellia resin constituents, with boswellic acids proposed to reduce hepatic inflammation by suppressing cytokine cascades and oxidative stress in liver tissue.

## Mechanism of Action

AKBA (3-O-acetyl-11-keto-β-boswellic acid) is the most pharmacologically potent boswellic acid and acts as a non-redox, non-competitive inhibitor of 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid to pro-inflammatory leukotrienes at IC50 values of approximately 0.6–15 µM and achieving up to 60% enzyme inhibition at 15 µM; AKBA also inhibits cathepsin G at an IC50 of 0.6 µM and suppresses DNA, RNA, and protein synthesis at IC50 values of 0.6, 0.5, and 4.1 µM respectively. At the transcriptional level, boswellic acids downregulate NF-κB nuclear translocation, attenuate MAPK phosphorylation cascades, and suppress COX-2 gene expression, collectively reducing [prostaglandin](/ingredients/condition/inflammation) and cytokine output. In immune cells such as neutrophils, boswellic acids stimulate [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) production via NADPH oxidase and MAPK in a calcium-dependent manner to support [antimicrobial](/ingredients/condition/immune-support) phagocytosis, while in non-immune cells they paradoxically activate Nrf2, inducing cytoprotective antioxidant gene expression. Additional molecular effects include modulation of the NLRP3 inflammasome, inhibition of complement activation, and promotion of [autophagy](/ingredients/condition/longevity)-mediated clearance of inflammatory mediators.

## Clinical Summary

Clinical research on boswellic acids has focused primarily on osteoarthritis of the knee, with several small randomized, double-blind, placebo-controlled trials evaluating standardized Boswellia serrata extracts at doses equivalent to 333 mg BSE capsules. Outcomes measured include visual analogue scale (VAS) pain scores, physical function indices, and walking distance, with some trials reporting statistically significant improvements versus placebo, though effect sizes vary and pooled meta-analytic data are limited. Pharmacokinetic data from a 12-subject study confirmed dose-dependent plasma exposure for multiple boswellic acids, validating systemic absorption, but the inter-individual variability was high and bioavailability remains suboptimal without formulation enhancements. Overall confidence in the clinical efficacy of boswellic acids is moderate for [anti-inflammatory](/ingredients/condition/inflammation) and joint-health endpoints but requires validation through larger, well-powered multicenter RCTs with standardized extract compositions.

## Nutritional Profile

Boswellic acids are not macronutrients or conventional micronutrients; they are bioactive pentacyclic triterpenoid acids present exclusively in Boswellia resin with no meaningful caloric, protein, carbohydrate, or fat contribution at supplemental doses. The crude resin contains total boswellic acids at concentrations of 20–60 mg/g, with β-boswellic acid at 10–20 mg/g and α-boswellic acid at 5–15 mg/g as the dominant individual compounds; KBA and AKBA are present in smaller but pharmacologically critical quantities. Boswellia resin also contains essential oils (e.g., α-thujene, p-cymene), polysaccharides, and minor terpenoids that may contribute to the overall biological activity of whole-resin preparations but are absent in highly purified boswellic acid extracts. Bioavailability of individual boswellic acids is inherently low due to extensive first-pass hepatic [metabolism](/ingredients/condition/weight-management) by CYP450 phase I and phase II enzymes and poor aqueous solubility; co-ingestion with dietary lipids and use of phospholipid-complexed formulations significantly improves systemic exposure.

## Dosage & Preparation

- **Standardized Boswellia serrata Extract (BSE) Capsules**: Typical doses studied are 333 mg BSE per capsule, with commercial products such as WokVel™ containing 18.51% β-BA, 6.93% α-BA, 8.58% β-ABA, and 1.85% α-ABA; daily doses in clinical studies generally range from 300–1,200 mg of standardized extract.
- **AKBA-Enriched Extracts**: Some preparations are standardized to minimum 30–40% total boswellic acids or specifically to AKBA content; higher AKBA standardization is associated with enhanced 5-LOX inhibitory potency in preclinical models.
- **Phytosome and Enhanced-Bioavailability Formulations**: Phospholipid complexes (phytosomes) and proprietary absorption-enhancement technologies are available to improve gastrointestinal absorption and extend plasma residence time, partially compensating for the inherent poor oral bioavailability driven by P450 [metabolism](/ingredients/condition/weight-management).
- **Traditional Resin/Gum Preparation**: Raw frankincense resin has been consumed orally, burned as incense, or applied topically in Ayurvedic and Unani medicine; raw resin contains 20–60 mg/g total boswellic acids but lacks dose precision.
- **Timing**: Supplemental BSE is typically taken with meals containing dietary fat to enhance absorption of these lipophilic triterpenoids; twice-daily dosing is common in clinical trial protocols to maintain plasma concentrations.
- **Standardization Note**: Look for products specifying both total boswellic acid content and individual AKBA percentage, as HPLC-verified extracts with detection limits near 0.040 µg/mL for KBA provide the most reliable pharmacological activity.

## Safety & Drug Interactions

Standardized Boswellia serrata extracts and purified boswellic acids are generally well tolerated at doses used in clinical studies (300–1,200 mg BSE/day), with the most commonly reported adverse effects being mild gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort, occurring infrequently and typically resolving without discontinuation. Because boswellic acids are substrates of CYP450 phase I and phase II metabolic enzymes, clinically meaningful drug interactions are theoretically possible with medications that share these metabolic pathways, including anticoagulants, immunosuppressants, and certain chemotherapeutics, although specific interaction studies in humans are largely absent from the published literature. No established maximum tolerated dose in humans has been formally defined through dose-escalation studies, and long-term safety data beyond short clinical trial durations (typically 8–16 weeks) are insufficient to confirm the absence of cumulative toxicity. Boswellic acids are not recommended during pregnancy or lactation due to the absence of controlled safety data in these populations, and individuals with known hypersensitivity to Boswellia species or frankincense should avoid use.

## Scientific Research

The clinical evidence base for boswellic acids is predominantly composed of small-scale pharmacokinetic studies, in vitro mechanistic work, and animal models, with limited large randomized controlled trials. One published pharmacokinetic study enrolled 12 healthy male volunteers receiving 333 mg of WokVel™ BSE, confirming systemic absorption of multiple boswellic acids via HPLC-ESI/MS, with β-BA reaching steady-state plasma concentrations in the range of 87–11,948 ng/mL and peak plasma levels of approximately 4.9 ± 0.5 µM for β-BA and 6.35 ± 0.5 µM for ABA. Rodent studies have documented brain penetration of KBA and AKBA at tissue concentrations of roughly 95–99 ng/g, supporting CNS bioavailability, while in vitro assays consistently reproduce 5-LOX inhibition, NF-κB suppression, and [cytokine](/ingredients/condition/inflammation) reduction at physiologically plausible concentrations. Several small RCTs investigating standardized BSE in osteoarthritis populations have reported reductions in pain scores and improvements in function, but these trials are limited by small sample sizes, heterogeneous extract standardization, and short follow-up durations, making definitive efficacy conclusions premature.

## Historical & Cultural Context

Frankincense resin from Boswellia species has been used for over 5,000 years in Ayurvedic medicine (as 'Shallaki'), Unani medicine, and ancient Egyptian, Greek, and Roman traditions, where it was applied for wound healing, pain relief, inflammatory conditions, and respiratory ailments. In the Ayurvedic pharmacopoeia, Boswellia serrata resin is classified as an analgesic, immunosuppressant, antileukemic, and [hepatoprotective](/ingredients/condition/detox) agent, traditionally prepared as a water decoction, powdered resin formulation, or oil-based extract for oral and topical use. Frankincense held profound cultural and religious significance across the ancient world, referenced in the Hebrew Bible, Egyptian papyri, and Dioscorides' De Materia Medica, and was traded along the Incense Route as one of the most valuable commodities of antiquity. Modern phytochemical research beginning in the late 20th century isolated and characterized the specific boswellic acid constituents responsible for the observed [anti-inflammatory](/ingredients/condition/inflammation) bioactivity, bridging millennia of empirical traditional use with molecular pharmacology.

## Synergistic Combinations

Boswellic acids and curcumin (from Curcuma longa) represent a well-recognized combinatorial stack in which 5-LOX inhibition by AKBA and COX-2/NF-κB suppression by curcumin target complementary nodes of the arachidonic acid inflammatory cascade, producing additive to potentially synergistic [anti-inflammatory](/ingredients/condition/inflammation) effects relevant to arthritis and inflammatory bowel disease. Combining boswellic acids with piperine (black pepper extract) leverages piperine's inhibition of CYP3A4-mediated [metabolism](/ingredients/condition/weight-management) and P-glycoprotein efflux to enhance systemic bioavailability of boswellic acids, a pairing frequently incorporated into commercial formulations. Preliminary [antimicrobial](/ingredients/condition/immune-support) data suggest synergy between boswellic acids and conventional beta-lactam or glycopeptide antibiotics against Gram-positive pathogens, though this application lacks clinical validation and represents an area of exploratory rather than established use.

## Frequently Asked Questions

### What are boswellic acids and what do they do?

Boswellic acids are a group of pentacyclic triterpenoid compounds extracted from the resin of Boswellia serrata (Indian frankincense), with the most potent being AKBA (3-O-acetyl-11-keto-β-boswellic acid). They exert anti-inflammatory effects primarily by inhibiting the enzyme 5-lipoxygenase (5-LOX) at IC50 values of 0.6–15 µM, thereby blocking leukotriene synthesis, and by suppressing NF-κB and COX-2 signaling pathways that drive chronic inflammation.

### How much boswellic acid should I take for arthritis?

Clinical studies investigating Boswellia serrata extract for osteoarthritis have most commonly used doses of 333–1,200 mg of standardized BSE per day, often divided into two or three doses taken with meals to improve absorption of these fat-soluble compounds. Products should ideally be standardized to a defined percentage of total boswellic acids or AKBA content; however, no universally accepted clinical dosing guideline has been established, and individuals should consult a healthcare provider before beginning supplementation.

### Are boswellic acids the same as frankincense?

Frankincense refers to the whole oleo-gum resin tapped from Boswellia trees, which contains a complex mixture including essential oils, polysaccharides, and roughly 20–60 mg/g of total boswellic acids among other constituents. Boswellic acids are the specific class of pentacyclic triterpenoid compounds within frankincense resin that are primarily responsible for its documented anti-inflammatory pharmacological activity, so while all boswellic acids come from frankincense, frankincense is not purely boswellic acids.

### Do boswellic acids have any side effects or drug interactions?

At typical supplemental doses (300–1,200 mg BSE/day), boswellic acids are generally well tolerated, with mild gastrointestinal symptoms such as nausea or diarrhea being the most frequently reported adverse effects. Because they are metabolized by CYP450 phase I and II enzymes, potential interactions exist with drugs sharing these pathways—including anticoagulants, immunosuppressants, and some chemotherapy agents—though human interaction studies are largely lacking, making caution advisable when combining with prescription medications.

### What is the most potent boswellic acid compound?

AKBA (3-O-acetyl-11-keto-β-boswellic acid) is generally considered the most pharmacologically potent of the boswellic acids, demonstrating 5-LOX inhibition at an IC50 as low as 0.6 µM and cathepsin G inhibition at the same concentration, along with suppression of DNA and RNA synthesis. KBA (11-keto-β-boswellic acid) also contributes meaningfully to anti-inflammatory activity, and commercial extracts vary significantly in their AKBA and KBA content, which is why standardization of extract concentration is critical for consistent therapeutic effects.

### What is the difference between AKBA and KBA in boswellic acid supplements?

AKBA (acetyl-11-keto-beta-boswellic acid) and KBA (11-keto-beta-boswellic acid) are the two most bioactive boswellic acids, with AKBA being the most potent inhibitor of 5-lipoxygenase at nanomolar concentrations. KBA also demonstrates significant anti-inflammatory activity but requires slightly higher concentrations to achieve similar 5-lipoxygenase inhibition. High-quality Boswellia serrata extracts are often standardized to contain elevated levels of both compounds to maximize anti-inflammatory efficacy.

### How does boswellic acid absorption affect its effectiveness?

Boswellic acids have relatively poor bioavailability when taken orally, with absorption enhanced by consumption with meals containing fat or lipids. Standardized extracts with higher AKBA and KBA concentrations show improved therapeutic outcomes in clinical studies compared to lower-potency preparations. Some formulations include bioavailability enhancers or are designed as lipophilic complexes to improve gastrointestinal absorption and systemic delivery.

### Is boswellic acid supplementation appropriate for inflammatory bowel conditions?

Clinical evidence suggests boswellic acids may benefit inflammatory bowel conditions through dual mechanisms: inhibiting 5-lipoxygenase to reduce leukotriene biosynthesis and suppressing NF-κB signaling to attenuate intestinal inflammation. However, individuals with active inflammatory bowel disease should consult a healthcare provider before supplementing, as boswellia may interact with immunosuppressant medications commonly used for these conditions. The research base for IBD applications is smaller than for osteoarthritis, so evidence quality varies.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*